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The effects of adding tramadol to ropivacaine on
axillary brachial plexus blockade in uremic patients*
Aim: To evaluate the effect of tramadol added to ropivacaine on quality of anesthesia, onset of sensory
and motor blockade, duration of sensory and motor blockade, and first analgesic request time for
axillary brachial plexus block in uremic patients.
Materials and methods: After institutional approval and informed consent had been obtained, 45
ASA III uremic patients (age range 30-80) scheduled for arteriovenous fistula surgery were included
in the study. Patients were randomly allocated into 2 groups. Axillary block was performed with a
peripheral nerve stimulator by multiple injection technique. Patients in Group R (n = 23) received
38 mL of ropivacaine (3.75 mg/mL) and 2 mL of normal saline, and patients in group RT (n = 22)
received 38 mL of ropivacaine (3.75 mg/mL) and 2 mL of tramadol (50 mg/mL). The onset and
duration of sensory and motor block in the distribution of the radial, median, and ulnar nerves; the
duration of analgesia; the time to first requirement of analgesic; hemodynamics; and side effects were
recorded.
Results: Demographic data, onset of sensory and motor block, duration of sensory and motor block,
quality of anesthesia, and first analgesic requirement times were similar between the groups. In
addition, hemodynamic parameters and side effects did not differ between the groups.
Conclusion: The addition of 100 mg of tramadol to 3.75 mg/mL of ropivacaine does not have any
beneficial effect on the nerve block characteristics of axillary brachial plexus anesthesia for
arteriovenous fistula surgery in uremic patients.
Key words: Axillary brachial plexus block, ropivacaine, tramadol, chronic renal failure

Üremik hastalarda aksiller brakial pleksus bloğunda ropikaine eklenen
tramadolün etkisi
Amaç: Bu çalışma; üremik hastalarda aksiler brakial pleksus bloğunda ropivakaine tramadol
eklenmesinin anestezi kalitesi, duyusal ve motor blok süresi ve ilk analjezik gereksinim üzerine
etkisini değerlendirmek için tasarlanmıştır.
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Yöntem ve gereçler: Etik kurul onayı ve bilgilendirimiş hasta oluru alındıktan sonra arteriovenöz
fistül operasyonu düşünülen kırkbeş ASA III üremik hasta (30-80 yaş arası) rastgele iki gruba ayrıldı.
Aksiller blok sinir stimülatörü kullanılarak multiple enjeksiyon tekniği ile yapıldı. Grup R’deki
hastalara (n = 23) 38 mL ropivakain (3,75 mg/mL) ve 2 mL serum fizyolojik ve Grup RT’deki hastalara
(n = 23) 38 mL ropivakain (3,75 mg/mL) ve 2 mL tramadol (50 mg/mL) uygulandı. Radial, median
ve ulnar sinirlere ait duyusal ve motor blok başlama zamanı ve süreleri, analjezi süresi, ilk analjezik
gereksinim zamanı, hemodinami ve yan etkiler kaydedildi.
Bulgular: Demografik data, duyusal ve motor blok başlama zamanı ve duyusal ve motor blok başlama
süreleri, analjezi süresi, anestezi kalitesi ve ilk analjezik gereksinim zamanı açısından her iki grup
arasında benzerdi. Bununla birlikte, hemodinamik parametreler ve yan etkiler açısından da fark
yoktu.
Sonuç: Üremik hastalarda, arteriovenöz fistül operasyonu için aksiler brakiyal pleksus anestezisinde
3,75 mg/mL ropivakaine 100 mg tramadol eklenmesi, sinir blok karakteristikleri üzerine yararlı etki
göstermemiştir.
Anahtar sözcükler: Aksiller brakiyal pleksus blok, ropivakain, tramadol, kronik böbrek yetmezliği

eyuphorasanli@yahoo.com

* This study was presented at Euroanesthesia meeting 2007 in Munich, Germany
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Introduction
Patients with chronic renal failure (CRF) most
commonly present to the operating room for creation
or revision of an arteriovenous fistula under local or
general anesthesia (1). Many anesthesiologists prefer
brachial plexus block as a suitable anesthesia
technique for this procedure (2,3). The resulting
analgesia and sympathetic blockade provide optimal
surgical conditions, and subsequently adequate
duration of postoperative block prevents arterial
spasm and graft thrombosis. In the early
postoperative period, the arteriovenous fistula blood
flow was shown to be significantly increased in
patients having brachial plexus blockade when
compared to those having halothane or isoflurane
anesthesia (4). It is reported that the local anesthetics
were absorbed faster from the axillary region into
circulation and due to reduced clearance of them their
plasma concentrations were higher in CRF patients
(5). Moreover, the hyperdynamic cardiovascular
system and metabolic acidosis secondary to chronic
anemia increase the elimination rate of local
anesthetics, resulting in a shorter duration of the
axillary block compared to those with normal renal
function (2,6).
Ropivacaine was used for axillary block with high
efficacy and safety (7-9). Since the metabolites of
ropivacaine are excreted in urine, the potentially toxic
metabolites may accumulate in chronic renal failure
patients (10). This is why lower concentrations of
ropivacaine are recommended in patients with
chronic renal failure when large doses are planned to
be used (5). However, it is reported that brachial
plexus block was performed with a smaller
ropivacaine concentration in patients with chronic
renal failure; the duration of analgesia was shorter
than the higher ropivacaine concentration in patients
with normal renal function (11). The addition of
tramadol to local anesthetics significantly prolonged
the duration of brachial plexus block in patients with
normal renal function (12-14). Tramadol is one of the
least problematic opioids for patients with chronic
renal failure (15). Tramadol seems to be a good
alternative for additionally providing the above
mentioned.
On the basis of these data we aimed to evaluate the
effects of tramadol as an adjuvant to ropivacaine on
734
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the onset and duration of sensory and motor
blockade, quality of anesthesia, and first analgesic
request time for axillary brachial plexus blockade in
CRF patients.
Materials and methods
After approval from the hospital’s Ethics
Committee and written informed patient consent
were obtained, 45 patients with chronic end-stage
renal disease that were scheduled for creation of an
arteriovenous fistula were included in the study. The
ages of the patients ranged between 30 and 80 years
and all were ASA physical status III. The exclusion
criteria were a body weight more than 130 kg, height
less than 140 cm, or a history of neurological,
neuromuscular, psychiatric, hepatic, respiratory, or
cardiac disorders.
The patients received premedication with
midazolam 1-2 mg IV at the discretion of the
anesthesiologist. Three-lead electrocardiogram,
noninvasive oscillotonometric arterial blood pressure,
and pulse oxymetry (ADU S/5 Datex-Ohmeda,
Finland) were used for monitoring. An IV infusion of
normal saline 250 mL/h was started before anesthesia.
The randomization was performed from a list of
random numbers; instructions for randomization
were prepared in a sealed envelope for each patient.
The patients were allocated into 1 of the 2 groups for
axillary brachial plexus block.
The patient was placed in a supine position with
the arm abducted 90° and the elbow flexed 90° to
identify the pulse of the axillary artery. The area was
prepared with povidone-iodine solution and multiple
injections were performed to obtain a perivascular
axillary brachial plexus block. Each nerve was
identified with a short, beveled electrical stimulation
needle (Stimuplex, B. Braun Melsungen AG,
Melsungen, Germany) connected to a nerve
stimulator using low currents. Fourteen milliliters of
the study solution was injected near each nerve with
intermittent aspiration, after the nerves were
identified by obtaining a peripheral motor response
with a current near or below 0.5 mA. The study
solution consisted of 40 mL of ropivacaine (Naropin,
AstraZeneca, Sweden) 3.75 mg/mL and 2 mL of saline
in Group R, whereas it contained 40 mL of
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ropivacaine 3.75 mg/mL and 2 mL of tramadol 100
mg in Group RT. The patients were informed about
the signs of local anesthetic toxicity before the
injections and the verbal contact was maintained until
the end of the injection period. Firm digital pressure
was maintained during the injection and 3 min
thereafter immediately distal to the injection site to
prevent flow of the solutions distally. Following
injection, the arm was kept adducted with the hand
resting on the chest. Sensory block was assessed in the
innervation areas of the median, radial, and ulnar
nerves by pinprick testing. Pinprick testing was
performed using a blunt-ended 27-gauge dental
needle at 0, 2, 5, 10, 20, and 30 min and then every 15
min during the procedure. The patients assessed the
pinprick sensation as sharp (normal sensation), blunt
(analgesia), or no sensation of touch (anesthesia). The
motor block was assessed by thumb abduction (radial
nerve), thumb adduction (ulnar nerve), and thumb
opposition (median nerve) on a 3-point scale for
motor function (0 = normal motor function, 1 =
reduced motor strength but able to move finger, 2 =
complete motor block) with the same intervals as the
pinprick.

prilocaine into the surgical site if the block was not
achieved in this site after 45 min. Fentanyl 0.05-0.1
mg was administered IV if the patient experienced
pain despite the block. The patients with anxiety were
administered IV midazolam 1-2 mg.

The duration of anesthesia was defined as the time
interval between the onset of analgesia and the
recovery of sensation of touch. The duration of motor
block was defined as the time interval between the
onset of the motor block and the recovery from the
motor block. The surgery started when pinprick
anesthesia was achieved in the regions of the median,
radial, and ulnar nerves. The surgeon injected 1%

Five of the 45 patients originally included in the
study were subsequently excluded because the
anesthesia could not be achieved in 3 patients in
Group R after 45 min and the radial nerve could not
be identified in 2 patients in Group RT.

A visual analog scale (VAS) was used to assess pain
at 0, 1, 2, 4, 8, 12, and 24 h postoperatively. Heart rate,
blood pressure, oxygen saturation, respiratory rate,
and sedation scores were recorded at the same time
points. Nausea and vomiting were recorded if present.
The duration of anesthesia was defined as the time
between the local anesthetic injection and the time
that the first analgesic was required.
The data were analyzed using SPSS 13.0 for
Windows (SPSS Inc., Chicago, IL, USA). Patient
characteristics and times were analyzed for normality
and the 2 groups were compared using Student’s t-test.
Categorical data were analyzed using the chi-squared
test. Data were expressed as the mean ± SD and
patient numbers as appropriate. A P value of less than
0.05 was considered statistically significant.
Results

The demographic data, ASA physical status, and
surgical characteristics were similar between the 2
groups (Table 1, P > 0.05).

Table 1. Demographic data and surgical characteristics (mean ± SD).

Age (years)
Body weight (kg)
Height (cm)
Gender (M/F)
Surgery start (min)
Duration of surgery (min)

Group R
(n = 20)

Group RT
(n = 20)

P

55.1 ± 14.5
60.7 ± 10.4
162.1 ± 10.7
5/15
20.4 ± 11.9
51.6 ± 15.2

61.5 ± 10.9
67.7 ± 12.9
164.8 ± 6.7
6/14
22.6 ± 6.8
50.9 ± 14.3

0.229
0.312
0.385
1.000
0.229
0.693

R, ropivacaine only; RT, ropivacaine+tramadol. Values are mean ± standard deviation
or n
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Time to onset for the sensory block and the
duration of the sensory block showed no differences
between the groups (Table 2, P > 0.05). The groups
also did not differ in terms of the time to onset for the
motor block or its duration (Table 3, P > 0.05).
Average time to first requirement of analgesic was
218.9 ± 39.0 min in Group R and 233.7 ± 22.2 min for
Group RT with no differences between the groups (P
= 0.176). VAS scores were similar between the groups
(P > 0.05) except for at 2 h postoperatively (P = 0.042).
The groups were similar in terms of the need for
an analgesic supplement or sedation during the
procedure (P > 0.05). It was noted that the patients in
Group R needed sedation more frequently, but the
difference between the groups was not significant (P
> 0.05).
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There were no significant differences between the
groups in terms of the sedation scores, or respiratory
or hemodynamic parameters (P > 0.05). Side effects,
such as hypotension and bradycardia, were not
observed in either group during the study period.
Three patients in Group RT and 1 patient in Group R
experienced nausea/vomiting, but there were no
statistically significant differences between the groups.
Discussion
In this study, we achieved a sufficient and goodquality axillary plexus block with 40 mL of 3.75
mg/mL ropivacaine (150 mg) for creation of an
arteriovenous fistula in patients with chronic renal
failure. Although these parameters were not
statistically significant adding tramadol to ropivacaine

Table 2. Onset time and duration of sensory block for analgesia (mean ± SD).
Group R
(n = 20)

Group RT
(n = 20)

P

6.01 ± 1.4

5.2 ± 1.1

0.093

197.9 ± 32.6

220.1 ± 22.7

0.806

6.5 ± 1.5

5.9 ± 1.4

0.322

Duration of median nerve sensory block

201.4 ± 29.3

222 ± 23.2

0.045

Onset time of ulnar nerve sensory block

6.71 ± 1.4

5.7 ± 1.3

0.092

205.7 ± 29.8

221.3 ± 22.6

0.122

Onset time of radial nerve sensory block
Duration of radial nerve sensory block
Onset time of median nerve sensory block

Duration of ulnar nerve sensory block

R, ropivacaine only; RT, ropivacaine+tramadol. Values are mean ± standard deviation or n

Table 3. Onset time and duration of motor block (mean ± SD).
Group R
(n = 20)
Onset time of radial nerve motor block
Duration of radial nerve motor block
Onset time of median nerve motor block
Duration of median nerve motor block
Onset time of ulnar nerve motor block
Duration of ulnar nerve motor block

Group RT
(n = 20)

8.7 ± 2.3

8 ± 1.9

0.876

195.7 ± 37.1

192 ± 26.9

0.965

8.1 ± 1.6

8.5 ± 1.7

0.282

198.6 ± 35.2

192 ± 27.4

0.743

8.1 ± 1.4

8.1 ± 1.9

0.912

197.9 ± 36.8

192.7 ± 26.8

0.759

R, ropivacaine only; RT, ropivacaine+tramadol. Values are mean ± standard deviation or n
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clinically shortened the time to onset for the sensory
block and increased the duration of it minimally
without changing the block characteristics. The time
to requirement for an analgesic was relatively delayed
when tramadol was added to ropivacaine.
Bupivacaine is a frequently used local anesthetic
and has the clinical advantages of long duration of
action and favorable ratio of sensory to motor neural
block. Ropivacaine may potentially provide better
success rates for axillary brachial plexus block than
bupivacaine, because it enables larger doses to be used
owing to its low cardiotoxicity (7,8). It was reported
that 0.25% ropivacaine is similar in quality to 0.25%
bupivacaine in most aspects for brachial plexus block.
As both of them are frequently associated with
inadequate sensory and/or motor block, Hickey et al.
(16) recommended 0.5% concentration for both.
Vainnionpaa et al. (17) reported that both bupivacaine
and ropivacaine were equally effective for an axillary
brachial plexus block at a concentration of 0.5%. This
result was confirmed by McGlade et al. (18) and
Bertini et al. (19), who reported that ropivacaine was
better suited for axillary brachial plexus block than
bupivacaine, and increasing the ropivacaine
concentration increased the risk of systemic toxicity
without any clinical advantages.
Pere et al. used 7.5 mg/mL ropivacaine (total 300
mg) for axillary block in uremic and non-uremic
patients. Pharmacokinetic data in the study with
ropivacaine showed that faster absorption into
circulation and increased binding α1-acid
glycoprotein, reducing liver extraction, led to
significantly higher plasma concentrations of
ropivacaine and its metabolites in uremic patients.
However, the quality of sensory and motor block was
similar between the uremic and non-uremic patients.
No toxic symptoms occurred despite occasional large
plasma concentrations soon after the injection of
ropivacaine (20).
Ropivacaine is not excreted through the kidneys
and therefore impairment of renal function does not
impair its elimination. However, because renal
function is important for elimination of 2,6
pipecoloxylide (PPX) and 3-OH-ropivacaine, renal
insufficiency may cause accumulation of those
compounds. Large concentrations of PPX may
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unexpectedly develop (20). The free plasma
concentrations of PPX (80%-90% of the total) may
reach the toxic level although PPX is clearly less toxic
than ropivacaine (11).
We used 3.75 mg/mL (150 mg) ropivacaine for
creation of arteriovenous fistula in chronic renal
failure patients because the aforementioned factors.
The mean onset time of analgesia was 6.4 ± 1.4 min
and the duration of anesthesia was 201.7 ± 30.6 min in
different dermatomes of the brachial plexus. When
used for brachial plexus block, the onset time
depended on the technique used. The onset times for
analgesia and anesthesia ranged from 11.2 to 20.2 min
and 23.3 to 48.2 min, respectively, with a
concentration of 0.25% ropivacaine for subclavian
brachial plexus block (19). Analgesia in different
brachial plexus dermatomes was achieved in 5-20 min
and anesthesia in 12-45 min with a concentration of
0.5% ropivacaine for axillary plexus block (17). The
mean duration of analgesia and anesthesia ranged
from 9.2 to 13 h and 5 to 10.2 h, respectively, with the
concentration of 0.25% ropivacaine for subclavian
brachial plexus block (16). The duration of anesthesia
produced by 0.5% ropivacaine via axillary block
ranged from 3.7 to 8.7 h. The duration of anesthesia in
CRF patients was relatively short in our study and this
may have been due to acidosis and hyperdynamic
circulatory status, which increase the elimination rate
of local anesthetics, resulting in a shorter duration of
the axillary block compared to those with normal
renal function.
Tramadol is an analgesic that acts at central and
peripheral μ-opioid and monoaminergic receptors
(21). It also exhibits local anesthetic properties (22).
There have been few studies on adjunctive tramadol
for peripheral nerve blocks. Büyükakıllı et al.
examined the interaction of tramadol plus
bupivacaine on compound nerve action potential in
an isolated frog sciatic nerve (23). They reported that
the addition of tramadol to bupivacaine did not
enhance local anesthetic nerve block. Antonucci et al.
reported that the effects of tramadol 100 mg
combined with ropivacaine 0.75% prolonged
analgesia and anesthesia of brachial plexus block with
less adverse effects than clonidine and sufentanil (13).
The investigators used tramadol added at a lower dose
and volume (150 mg, 20 mL) of injectate at 0.75%
737
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concentration of ropivacaine under axillary block for
patients with normal renal function undergoing
carpal tunnel release. However, Kesimci et al. (24)
demonstrated that the addition of 100 mg of tramadol
to 7.5 mg/mL of ropivacaine, for axillary brachial
plexus block, did not prolong the duration of motor
and sensory block and analgesia. Similarly, Mannion
et al. did not demonstrate a clinically important local
anesthetic or peripheral analgesic effect of tramadol
as an adjunct to psoas compartment block with
levobupivacaine 0.5% (25). Our results were
consistent with the experience of Kesimci et al.
Although it is difficult to compare these contradictory
results due to differences in dose and concentration
of local anesthetic and technique of block, the patients
with CRF in our study had metabolic acidosis and
hyperdynamic circulatory status, which may mask the
effect of additional tramadol on axillary brachial
plexus block with ropivacaine (0.375%, 40 mL).
Kapral et al. demonstrated that adding tramadol
100 mg to mepivacaine 1% prolonged the duration of
both motor and sensory blocks in axillary brachial
plexus block (12). Wakhlo et al. reported that
tramadol was a good agent for quickening the onset
and prolonging of sensory and motor block, while
butorphanol was a suitable agent for prolonged
postoperative analgesia (26). Although Robaux et al.
demonstrated that the onset time for median and
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ulnar nerve blockade was shorter and the duration of
sensory and motor blockade was longer in tramadol
combined with mepivacaine 1.5% for brachial plexus
block, they reported that these differences were not
significant (14). In addition, tramadol significantly
increased the duration of postoperative analgesia in a
dose-dependent manner in this study. Kapral (12),
Robaux (14), and Wakhlo et al. (26) added tramadol
to short acting local anesthetics mepivacaine (1%,
1.5%) and lignocaine (2%) respectively in patients
with normal renal function. The lack of analgesic
effect of additional tramadol (100 mg) in our study
could be related to the choice of a long acting local
anesthetic (ropivacaine) at a dose (40 mL; 3.75
mg/mL) that provides long duration analgesia. This
may obscure any potential peripheral analgesic effect
of tramadol, and its administration into a
compartment versus into the brachial plexus sheath
may have been affected by the type, dose, and
concentration of local anesthetics.
In conclusion, a sufficient-quality axillary brachial
plexus block was achieved in both groups (3.75
mg/mL ropivacaine and 100 mg tramadol added 3.75
mg/mL in 40 mL) for creation of arteriovenous fistula
in patients with chronic renal failure. Further studies
with lower ropivacaine concentrations may offer
further clarification on the influence of tramadol on
axillary brachial plexus block characteristics.
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